I am Thomas Jack from germany. The focus of my talk is an often underestimated side effect of infusion therapy: particulate contamination. In my opinion, this issue does not receive the attention it deserves in clinical practice.
All infusion solutions we administer to patients carry a significant burden of particulate matter. These particles can originate from drug incompatibilities, formulation excipients, or may already be inherent in the drug preparations provided by pharmaceutical manufacturers.
While older experimental studies have long suggested that these particulates may be harmful, until now there has been no solid clinical evidence to support this concern.
In my presentation, I will share findings from the first clinical study conducted in a pediatric ICU, demonstrating that particulate contamination in infusion solutions is not just a theoretical risk—it can lead to serious, even disastrous outcomes. Most importantly, the study shows that by eliminating these particles, we can significantly improve patient outcomes.
